




16TH–19TH JUNE

2018

V I E N N A
WORLD CONGRESS

Neuropsychopharmacology: Meeting Global Challenges with Global Innovation





16TH–19TH JUNE
2018 VIENNA
WORLD CONGRESS



W: www.cinp.org E: cinp@cinp2018.org



Dr. John H. Krystal, USA
President, CINP



Prof. Barbara Sahakian, UK
*Chair, CINP International
Scientific Programme
Committee*



Prof. Marina Picciotto, USA
*Co-Chair, CINP International
Scientific Programme
Committee*



Prof. Siegfried Kasper, Austria
*Chair, Local Organizing
Committee and CINP
President-Elect*

Dates for your Diary

July 2017	Launch of conference programme/ Call for poster abstracts and award applications
July 2017	Registration Open
12th Jan 2018	First deadline for early registration fee
12th Jan 2018	Deadline for poster abstract submission
12th Jan 2018	Deadline for Award applications
12th Jan 2018	Deadline for speaker abstracts for accepted symposia
12th May 2018	Second deadline for registration fee
16th June 2018	Opening Ceremony of CINP 2018



16TH-19TH JUNE

2018

V I E N N A
WORLD CONGRESS

Neuropsychopharmacology: Meeting Global Challenges with Global Innovation



16TH – 19TH JUNE

2018

V I E N N A
WORLD CONGRESS



Preliminary Programme

Key

Saturday 16th June 2018		
09.00-10.30		PCW1 Holly Lisanby TMS
11.00-12.30	SAT1	PCW1 Eduard Vieta Bipolar
14.30-16.00	SAT2	PCW3 Joseph Zohar PTSD
16.45-18.00	Welcome and Awards Ceremony	

PL - Plenary

S - Symposia

CP – Clinical Perspectives

PCW/ WS – Pre-Conference
Workshop/ Education Workshop

CO – Corresponding Organisations

Sunday 17th June 2018

08.30-08.45	Opening Address						
08.45-09.30	PL01: The environment and resilience against mental illness Andreas Meyer Lindenberg, Germany						
09.45-11.30	Others	Schizophrenia	PTSD	ADD	Others	CP01	WS01
	S1: GABA regulation: from mechanisms to novel therapeutic targets	S2 : The use of technology in mental illness and mental wellbeing	S3: PTSD Genetics in a military context	S4: ADHD across the lifespan - biological mechanisms underlying disease onset and persistence, implications for treatment	S5: CINP initiative for public private partnerships (PPPs) for innovative CNS drug development	Addiction	Bipolar Disorders The place of CINP treatment guidelines for bipolar disorder in clinical practice: controversies and consensus
11.30-13.00	Poster Session and Lunch			Women's Symposium	CO1		
13.00-14.30	SAT3	SAT4	SAT5	Details to follow	Details to follow		
14.45-16.30	Depression	Others	Bipolar Disorders	Addictive Disorders	Depression	CP02	WS02
	S6: New approaches in transcranial magnetic stimulation for depression	S7: New insights into the role of orbitofrontal cortex in compulsive behavior psychopathology and its treatment	S8: Strategies to prevent neurobehavioral progression and suicide in bipolar disorder	S9: Cannabis shapes the morphological and epigenetic trajectory of mesocorticolimbic brain development relevant to psychiatric vulnerability	S10: Glutamate and mood disorders: All is not explained by NMDA	Schizophrenia	Childhood and Adolescent Disorders Advances in the diagnosis of paediatric mood disorders
16.45-17.30	PL02: Suicidal subtypes: improving phenotypes to uncover underlying biosignatures Maria A Oqendo, USA						
18.00-19.30	SAT6	SAT7	SAT8				

Monday 18th June 2018

08.45-09.30	PL03: Molecular mechanisms of gene x environment interactions - implications for diagnosis and treatment of psychiatric disorders Elisabeth Binder, Germany						
09.45-11.30	Depression	Depression	Presidential symposium	Addictive Disorders	OCD	Schizophrenia	WS03
	S11 : Prediction of disease vulnerability and treatment response in mood and anxiety disorders	S12: Translational research on etiopathogenesis of late-life cognitive impairment and depression: four different approaches toward the common goal	Details to follow	S13: A translational approach to reducing drug-related memories and enhancing self-control in drug addiction	S14: Translational neuroscience of obsessive-compulsive disorders	S15: Schizophrenia: From genes to changed brain function	Progress of the neuroscience-based nomenclature (NbN) for Psychotropic drugs
11.30-13.00	Poster Session and Lunch			Young Scientist Committee Meeting	CO2		
13.00-14.30	SAT9	SAT10	SAT11				
14.45-16.30	Depression	Depression	Addictive Disorders	Schizophrenia	LATE BREAKING	CP03	WS04
	S16: The antidepressant controversy: what do reanalyses of controlled trials reveal regarding the true efficacy of antidepressants?	S17: It's all in the wiring: Brain circuits involved in depression and antidepressant actions	S18: Behavioural addiction: a research and clinical update	S19: Dopamine signal intensity in neuropsychiatric disorders: etiology and therapy	S20	Rapid acting antidepressants	
16.45-17.30	PL04: Modeling and predicting developmental trajectories of neuropsychiatric dimensions Noboru Hiroi, USA						
18.00-19.30	SAT12	SAT13	SAT14				

Tuesday 19th June 2018

08.45-09.30	PL05: A circuits-first approach to mental illness Amit Etkin, USA						
09.45-11.30	Depression	OCD	Schizophrenia	Depression	Schizophrenia	CP04	WS05
	S21: Understanding the mechanism of action of ketamine-like drugs in mood disorders and their implementation in the clinic	S22: Deep brain stimulation for severe OCD: effect and mechanisms of STN and nucleus accumbens targets	S23: Recent updates on controversial issues in the management of schizophrenia	S24 : Neuroimaging in the treatment of depression - acute neuronal response, treatment effects and recurrence prediction	S25: NMDAR dysfunction, neuromodulatory dysfunction and glutathione deficit in schizophrenia pathogenesis	Treatment Resistant Depression	Neuropsychopharmacology of the endocannabinoidome
11.30-13.00	Poster Session and Lunch			General Assembly	CO3		
13.00-13.45	PL06: Glutamatergic GABAergic and dopaminergic abnormalities in antipsychotic-naïve first-episode schizophrenia patients: connected disturbances or independent biomarkers for outcome? Birte Glenthoej, Denmark						
13.45-15.30	Others	Others	Schizophrenia	Depression	LATE BREAKING	CP05	
	S26: Microbiome and neuropsychiatry - moving towards mechanisms	S27: Psychedelic medicine: the therapeutic potential of mind-altering substances	S28: Developing new medications for the treatment of schizophrenia: failures and hopes	S29: Genes epigenome and environment in pathophysiology of brain illness	S30	Anxiety Disorders and OCD	
15.30-16.15	PL07: Differential influence of pre- and early postnatal cannabis exposure on the developing brain Tibor Harkany, Austria						
16.15-16.30	Closing ceremony						



16TH – 19TH JUNE **V I E N N A**
2018 WORLD CONGRESS

W: www.cinp.org E: cinp@cinp2018.org



Early Bird Registration

Now Open!

Deadline 12th January 2018

Celebrate our

31st World Congress



www.cinp.org/vienna